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Abstract: As evidenced by the number of publications and patents published in the last years, 
the radiosynthesis of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine ([18F]FDOPA) using 
nucleophilic [18F]F- process remains currently a challenge for the radiochemists scientific 
community even if promising methods for the radiofluorination of electron-rich aromatic 
structures were recently developed from arylboronate, arylstannane or iodoniums salts 
precursors. In such context, based on the use of an iodonium triflate salt precursor, we 
optimized a fast and efficient radiofluorination route fully automated and free from any base, 
cryptand or metal catalyst for the radiosynthesis of [18F]FDOPA. Using this method, this 
clinically relevant radiotracer was produced in 64 min, 27-38% RCY d.c. (n = 5), >99% RCP, 
>99% e.e., and high molar activity 170-230 GBq/µmol. In addition, this optimisation study 
clearly highlighted the important role of a triflate-hydrogen carbonate counterion exchange 
during the radiolabelling process to achieve high fluorine-18 incorporation yields. 
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Introduction 
6-[18F]Fluoro-3,4-dihydroxy-L-phenylalanine ([18F]FDOPA) positron emission tomography 
(PET) imaging has been used for more than 30 years for a broad range of clinical applications[1] 
including diagnosis and follow up of neurodegenerative disorders,[2] brain tumours[3] and other 
malignant diseases.[4]  Despite its obvious clinical utility, [18F]FDOPA was underused primarily 
due to a lack of availability. Until a few years ago, the electrophilic substitution of the 
corresponding stannylated precursor with gaseous carrier added radioactive F2 was the only 
available radiosynthesis for this radiotracer, thus limiting to a few number of 
radiopharmaceutical centres the capacity to produce and deliver [18F]FDOPA. In addition to 
the difficulty of handling a radioactive gas, the use of carrier added radioactive F2 which 
displays low molar activity (Am) (0.1-0.6 GBq/µmol) was also problematic for the 
radiosynthesis of [18F]FDOPA due to the concomitant formation of non-radioactive [19F]FDOPA 
presenting potential pharmacological effects.[5] During the last decade, significant efforts have 
been deployed to access to [18F]FDOPA, from the widely available and no-carrier-added 
(n.c.a.) [18F]fluoride ions.[6] However, radiofluorination of such electron-rich aromatic structure 
via nucleophilic substitution remains a highly challenging task. The radiosynthesis of 
[18F]FDOPA is also hampered by the presence of an oxygen-sensitive catechol function and a 
chiral center requiring a careful control of the enantiomeric excess (e.e.). The most recent and 
marked examples of nucleophilic approaches overcoming these challenges are depicted in 
Figure 1. The fully automated multi-step radiosynthesis (Figure 1, method A) described by 
Lemaire et al.[7] was based on a classical aromatic nucleophilic substitution of an ortho-
activated trimethylammonium triflate precursor with [18F]fluoride ([18F]F-), followed by solid 
supported reduction and halogenation of the aldehyde function into benzyl iodide. The 
enantioselective introduction of the amino-acid part was achieved by alkylation with the tert-
butyl glycinate-benzophenone Schiff base in the presence of a chiral phase-transfer catalyst. 
Final deprotection with concentrated hydroiodic acid afforded [18F]FDOPA on the curie level 
with high radiochemical yield (RCY), Ma, enantiomeric excess (e.e.) and extraordinary short 
time of 65 min for such complex multi-step radiosynthesis procedure. Taking advantage of the 
most recent advances in radiofluorination of electron-rich aromatic rings, [18F]FDOPA has also 
been obtained with high RCY and e.e. by copper promoted carbon-fluorine coupling reaction 
on an arylboronate precursor[8,9] (Figure 1, methods B1 and B2). The protected [18F]FDOPA 
was also obtained with a high radiolabelling efficiency by copper promoted carbon-fluorine 
reaction starting from an arylstannane precursor[10] (Figure 1, method C) but the following 
deprotection step to afford [18F]FDOPA was not reported in this case. Finally, [18F]FDOPA was 
produced by [18F]F- nucleophilic substitution of an asymmetrical diaryliodonium salt[11] (Figure 
1, method D) followed by removal of the protecting groups.  
Despite later stage incorporation of fluorine-18, moderate decay-corrected (d.c.) RCY were 
obtained for strategies depicted in methods B1 and D (<15% or even less than 10% for copper-
mediated radiosynthesis when applied on a Synthra platform).  
 
Figure 1. n.c.a. radiosyntheses of [18F]FDOPA according to Lemaire et al.[7]  (method A), Tredwell et al.[8a] (method B1), Zischler 
et al.[8b] (method B2), Makavarage et al.[10] (method C) and Kuik et al.[11] (method D). 
Among other limitations, high amount of precursor was required for method B2 (i.e. 40 mg) 
while non-radioactive metal contamination, particularly copper, in the final solutions must be 
carefully assessed before human use for methods B and C.  
Among the aforementioned strategies and considering that reducing the overall radiosynthesis 
time remains a commonly used solution to enhance RCY with such short half-life radionuclide, 
we speculated that the relatively long reaction time of the iodonium salt procedure (i.e. 117 
min, Figure 1, Method D) could be shortened. We proposed to directly elute [18F]F- from the 
anion exchange QMA cartridge with an alcoholic solution of iodonium salts as previously 
described.[12] This strategy would also take advantage of eliminating base and cryptand of the 
reaction media in order to circumvent any decomposition of the reactive iodonium salt 
precursor under the harsh conditions used for radiolabelling of such structures.[13] Following 
these assumptions, we report here the development of a new fully automatic fast nucleophilic 
radiosynthesis of [18F]FDOPA free from any base, cryptand and metal catalyst. We also 
highlight in this manuscript that the success of such radiofluorination reaction is highly 
dependent of the nature on the iodonium precursor counter ion: herein a HCO3- anion. 
Results and Discussion 
Synthesis of diaryliodonium salt precursors 
 
According to slight modifications of the procedure previously published,[11] the target diaryl 
iodonium salt precursor 6b was obtained in five steps from commercially available L-DOPA. 
Briefly, 1 was produced by esterification and NH-Boc protection of starting material (Scheme 
1). Then, catechol hydroxy groups were selectively protected as ethoxymethyl ethers to give 
compound 2. Regioselective monoiodination with the combination of iodine and 
bis(trifluoroacetoxy)phenyl-λ3-iodane[14] provided 3 in 74% yield (the use of fleshly prepared 
bis(trifluoro)phenyl-λ3-iodane[15] is recommended to obtain reproducible and consistent yields). 
Compound 3 was converted into the bis-Boc protected derivative 4 to circumvent 
intramolecular interaction during the radiosynthesis between the iodine (III) center and the NH-
Boc function.[16] The fully protected compound 4 was converted into triflate diaryliodonium salt 
6b using a multistep one-pot procedure via the key intermediate (diacetoxyiodo)arene 5. The 
latter was prepared in situ by treatment of aryl iodine 4 with F-TEDA-2BF4 (Selectfluor©) and 
TMSOAc. Treatment of 5 with potassium (4-methoxyphenyl)trifluoroborate and TMSTFA gave 
the corresponding diaryliodonium trifluoroacetate salt. The trifluoroacetate counterion was then 
successively exchanged with acetate, hexafluorophosphate and finally triflate to give 
radiolabelling precursor 6b. 
 
Scheme 1. Preparation of diaryliodonium salts 6a-e. Reagents and conditions: (a) i) MeOH, SOCl2, 0 °C then reflux, 16 h; ii) 
(Boc)2O, THF, sat. aq. NaHCO3, RT, 2 h, 95%; (b) C2H5OCH2Cl, DIPEA, THF, 0 °C then 40 °C, 15 h, 99%; (c) I2, K2CO3, 
PhI(OCOCF3)2, CH2Cl2, RT, 2.5 h, 74%; (d) NEt3, DMAP, (Boc)2O, MeCN, RT, 29 h, 86%; (e) Selectfluor, TMSOAc, MeCN, RT, 
6.5 h; (f) i) TMSOCOCF3, p-MeOPhBF3K, MeCN, RT, 10 min; ii) 0.5 M aq. NaOAc/AcOH buffer (pH 5); iii) aq. NaPF6, MeCN, RT; 
iv) IRA-400 (TfO-) ion-exchange resin, 36%; (g) Sn2Me6, Pd(PPh3)4, 1,4-dioxane, reflux, 1.5 h, 91%; (h) i) p-MeOPh(IOAc)2, 
CH2Cl2, -40 °C, 1 h; ii)  TFA, -40 °C then RT, 5 h, 74%; (i) 1 M aq. NaOTf, CH2Cl2, RT, 85%; (j) 1 M aq. NaOTf, NaBF4, NaCl or 
NaClO4, CH2Cl2, RT, 87-95%. EOM: ethoxymethyl. 
Several modifications of the final synthesis step have been made. First, the use of a N2 charged 
glove-box necessary for the formation of a highly instable (difluoroiodo)arene intermediate, 
was substituted by a benchtop procedure under argon atmosphere. Moreover, the final 
isolation and purification of 6b by precipitation in MTBE was not successful and was replaced 
by silica gel column chromatography purification. These modifications could explain the lower 
yield obtained (36%) compared to the reported procedure (63%). Alternatively, to this time-
consuming and relatively complex one-pot reaction, we turned our attention to the recent 
development described by Wirth and co-workers[17] for solid-supported synthesis of iodonium 
salts. This strategy required the synthesis of trimethylstannane 7 from aryl iodine derivative 4 
using hexamethylditin and Pd(PPh3)4 as catalyst. Ligand exchange with 
(diacetoxyiodo)anisole[18] in the presence of TFA, added in a sequential manner at -40 °C, 
gave diaryliodonium trifluoroacetate 6a. Complete CF3CO2- to CF3SO3- exchange was then 
easily achieved by repeated washes of a solution of 6a in dichloromethane with an aqueous 
solution of NaOTf. According to this protocol, compound 6b was obtained over two steps in 
53% yield, comparable to the one described by Kuik et al.[11] (63%). Regardless to the methods 
used for the synthesis of 6b, the structural determinations were fully in agreement with the 
previously reported data (see supporting information). 
 
Radiofluorination of diaryliodonium salts 
 
We first tested as benchmark the previously reported radiofluorination method for [18F]FDOPA 
production via iodonium salt precursor 6b.[11] The radiosynthesis was performed on a 
SynChrom R&D Raytest EVOII platform using 935 to 4470 MBq of azeotropically dried K[18F]F-
crypt-222-carbonate complex and 11.2 ± 0.5 mg (13 µmol) of 6b in anhydrous diglyme at 
140 °C for 5 min. In these conditions, only 8.7 ± 2.3% (n = 3) of the protected radiofluorinated 
FDOPA derivative was obtained after solid phase C18 cartridge extraction. To increase the 
yield of incorporation of [18F]F- and try to reproduce the results of Kuik et al.[11] (i.e. RCY = 14% 
after deprotection), we increased the reaction time up to 15 min but without success. It should 
be noted that similar values (i.e. 4.5±1.3% RCY) were recently reported by Collins et al.[19] In 
the radiolabelling conditions described above, TLC-monitoring of the reaction mixture 
evidenced that no iodonium salt precursor can be detected by UV revelation of TLC plates 
already after 2 min at 140 °C highlighting the high instability of this compound under basic 
conditions (K2CO3/crypt-222). In addition, we clearly noticed that the sensitive precursor had 
to be freshly prepared, carefully stored under anhydrous argon atmosphere and protected from 
heat, light and moisture. 
We then turned our attention to the direct elution of [18F]F- from the anion exchange QMA 
cartridge with an alcoholic solution of iodonium salt 6b. Our optimisation study was divided in 
three parts: 1) elution of [18F]F- from the QMA cartridge, 2) incorporation of fluorine-18 on the 
protected structure, and 3) deprotection step leading to [18F]FDOPA. 
 
1/ Elution of [18F]F- from the QMA cartridge 
In order to prevent the decomposition of the precursor under basic conditions and avoid the 
time consuming drying procedure mandatory when using K2CO3/crypt-222, a direct elution of 
QMA-loaded [18F]F- with the diaryliodonium salt 6b was assessed. Based on the work of 
Richarz et al.[12b] describing a comparable minimalist approach, we compared different solvents 
or mixture of solvents for the elution of [18F]F- (Figure 2). Consistent with their findings, only 
protic solvents afforded suitable elution yields (62 to 97%) with a concentration of 13 µmol / 
750 µL of 6b while decreasing the volume of eluent, with the same amount of precursor, led to 
decreased elution yields (data not shown). Furthermore, any attempts to use an aprotic solvent 
such as acetonitrile, typically used in fluorine-18 radiochemistry processes, or mixture of 
aprotic and protic solvents decreased dramatically the elution yield (<16%). Finally, we found 
that a solution of precursor 6b (13 µmol) in a minimum of 750 µL of methanol revealed to be 
the most effective combination to elute [18F]F- initially trapped on the anion exchange cartridge 
(97 ± 0.03%, n = 41). 
 
Figure 2. Percentages (%, ratio between values of activity measured in the eluate and initially loaded onto the QMA cartridge, n 
= 2 except for MeOH: n = 41) of [18F]F- elution from QMA-HCO3
- cartridges depending on the solvent used for dissolution of the 
iodonium salt 6b (13 µmol in 750 µL); Mixture 1: MeCN/3-methylpentan-3-ol, 25/75, v/v; Mixture 2: MeCN/H2O, 90/10, v/v. 
Then, we intended to study the influence of the counterion of the iodonium precursor for the 
recovery of [18F]F- from the QMA cartridge. To this end, the five iodonium salts 6a-e (Scheme 
1) with Cl-, ClO4-, BF4-, CF3SO3- or CF3CO2- counterions were compared (Figure 3). When using 
classical QMA-HCO3- cartridges (SepPak Accell Plus QMA Plus Light cartridges, Waters, 130 
mg, preconditioned with K2CO3), moderate elution yields were obtained for the BF4- and 
CF3CO2-iodonium salts. The best results were observed with iodonium salts bearing Cl-, ClO4-, 
or CF3SO3- counterions (91, 86 and 97% respectively). We noted that the elution efficiency 
seemed to be correlated with pKb values of the corresponding counteranions tested. Indeed, 
the stronger the basicity of counterions is, the worse the elution of [18F]F- gets. As we suspected 
that all anions present in the reaction mixture could enter in competition with [18F]F- during the 
radiofluorination reaction, we also tried QMA cartridges preconditioned with the corresponding 
counterion (i.e. Cl-, ClO4-, BF4-, CF3SO3- or CF3CO2-). In all cases, this preconditioning strategy 
did not affect the trapping of [18F]F- on the anion exchange resin (always higher than 90%). 
However, for most of the evaluated anions, the elution yields were lower compared to QMA-
HCO3- cartridges (49% for Cl-, 14% for BF4-, 32% for CF3SO3- and 19% for CF3CO2-). 
Interestingly, only the ClO4- iodonium salt 6e provided comparable elution efficiencies (86% for 
the QMA-ClO4- vs. 85% for the QMA-HCO3-). These experiments highlighted that the HCO3- 
anions present on the exchange resin seem to play a key role in the elution process of the 
[18F]F-. To clarify this phenomenon, we tried to determine more precisely the chemical 
composition of the QMA-HCO3- cartridge eluates. For this study, we used the same 
preconditioned QMA-HCO3- cartridges described above and a methanolic solution of iodonium 
salt 6b which proved to be the most efficient media to elute [18F]F- (Figure 3). A solution of 
precursor 6b in methanol (13 µmol, 750 µL) was then passed through the cartridge and the 
alcohol was evaporated under reduced pressure (we noticed by TLC that the temperature of 
the bath had to be lower than 40 °C to prevent the thermal decomposition of 6b). First, a 
reduced quantity of precursor (<70%) was recovered from the QMA cartridge after evaporation 
of the eluate. Surprisingly, 1H NMR analysis of the residue in CD3OD (see Figure S1, 
supplementary information) indicated no significant modification of the structure of 6b while 
only 8% of the latter could still be detected in the eluate by 19F NMR (see Figure S2, supporting 
information). Keeping in mind that the counterions of diaryliodonium salts can be readily 
exchanged with numerous organic or mineral (di)anions,[20] we assumed that the eluted 
compound was the diaryliodonium hydrogen carbonate salt resulting from a supported CF3SO3-
/HCO3- exchange. 
 
Figure 3. Percentages (%, ratio between values of activity measured in the eluate and initially loaded onto the QMA cartridge, n 
= 2, except for QMA-HCO3
-, X = CF3SO3
-: n = 41) of [18F]F- elution from QMA-HCO3
- or QMA cartridges preconditioned with 
corresponding anions depending on the counterion of the iodonium salt used (13 µmol in 750 µL of methanol). 
In order to evaluate the exact amount of iodonium salt required to achieve a complete 
conversion of the counterion on the QMA-HCO3- cartridges, bis(4-methoxyphenyl)iodonium-4-
methylbenzenesulfonate (8) was used as a surrogate model. This iodonium salt was 
synthesised in one step from commercially available anisole in 43% yield (see supporting 
information). For the exchange study, a solution of iodonium salt 8 in CD3OD (750 µL) was 
passed through a QMA-HCO3- cartridge (beforehand washed with 1 mL of methanol and dried 
over an argon flow for one min). The percentage of counterion exchange was then assessed 
by 1H NMR in CD3OD. After elution a mixture of iodonium salts was observed. Nearly complete 
counterion exchange was obtained using less than 10 µmol of the iodonium salt 8 for the 
elution (Figure S3, supplementary information). All signals corresponding to the former tosylate 
counteranion could not be detected, confirming the complete exchange expected. 
All attempts to purify the eluted iodonium salt by column chromatography or crystallization 
remained unsuccessful and led to the complete decomposition of the eluted structure. This 
could be explained by the relatively low stability of iodonium hydrogen carbonate derivatives, 
which moreover are rarely found in the literature.[21] In fact, only the presence of the HCO3- 
counterion was evidenced on crude residue by IR analyses with a broad vibration band clearly 
visible at 1351 cm-1 (C=O) (see Figure S4, supplementary information). To confirm the nature 
of the eluted counterion, we tried to visualize the sp2 carbon of the HCO3- anion by NMR 13C 
analyses. Unfortunately, this signal could never be detected even with optimisation of the 
acquisition parameters. We then decided to use an enriched aqueous [13C]K2CO3 solution to 
equilibrate the QMA-HCO3- cartridge. Under these conditions, NMR 13C analysis of the eluate 
clearly highlighted the characteristic signal corresponding to the sp2 carbon of the HCO3- anion 
at 161.5 ppm (Figure 4). 
 
Figure 4. Comparison of 13C NMR spectra of starting iodonium salt 8 and eluate obtained after elution of a 13C-enriched QMA-
HCO3
- cartridge with 5 µmol of 8 showing the complete conversion of the tosylate derivative into its HCO3
- analogue. 
2/ Radiofluorination reaction 
In the next step, we evaluated the influence of such HCO3- exchanges on the radiosynthesis 
of [18F]FDOPA on a Raytest SynChrom R&D EVOII bireactor automate. [18F]F- was eluted from 
the QMA-HCO3- cartridge using 13 µmol of 6b in 750 µL of anhydrous methanol (elution yield: 
97 ± 0.03%, n = 41; % exchange to HCO3- counterion: 92% evaluated by 19F NMR). The 
obtained eluate was evaporated under vacuum at 30 °C to prevent any thermal decomposition 
of the precursor. Then, 750 µL of diglyme was added to the reactor and heated at 140 °C. For 
all time points checked, only around 3% of the desired fluorine-18 labelled intermediate [18F]9 
was observed. Interestingly, no increase over time could be detected. Also, variations of the 
temperature (90 °C, 110 °C, 140 °C, or 160 °C) did not increase the radiolabelling efficiency. 
When the amount of precursor used for the elution of the QMA-HCO3- cartridge was reduced 
(<13 µmol) to achieve a complete conversion of the counterion, no incorporation of the [18F]F- 
could be observed. Considering the loss of iodonium salt previously observed on the QMA-
HCO3- cartridges, we assume that the quantity of precursor present in the reactor was definitely 
too low to allow any [18F]F- incorporation. We then decided to investigate the influence of the 
precursor concentration, temperature and solvent used for the radiofluorination step. As 
highlighted in Figure 5A, increasing the concentration of the precursor 6b in diglyme while 
decreasing the temperature to 110 °C led to a significantly higher labelling efficiency (16% in 
100 µL diglyme at 110 °C vs <3% in 750 µL diglyme at 140 °C). Using the optimized 
concentration and temperature conditions, we tried to change the reaction solvent. The use of 
the aprotic polar solvents (DMF or DMSO) dramatically impacted the labelling efficiency which 
was lower than 3% for all attempts performed (data not shown). To reduce [18F]F-/HCO3- 
counteranion competition during the heating process, toluene was then tested as non-polar 
solvent and compared to diglyme. When using 200 µL of toluene at 110 °C for 10 min, the 
labelling efficiency was significantly higher (Figure 5B, 23 ± 4%, n = 6). Further modifications 
of the temperature or reaction time did not improve the percentage of incorporation of 
radioactive fluorides.  
In order to evaluate the impact of the CF3SO3-/HCO3- counterion exchange on the 
radiofluorination reaction, we used these optimized radiofluorination conditions on evaporated 
eluates obtained from QMA cartridges preconditioned with the same CF3SO3- counterion. In 
the absence of HCO3-, the reaction mixture rapidly turned black at 90-100 °C and less than 1% 
of the desired radiofluorinated product [18F]9 was detected. The same observation was made 
when using ClO4- derivative 6e and ClO4--preconditioned QMA-cartridge. These findings 
further confirmed the importance of the HCO3- counterion to ensure the success of the 
radiofluorination step. 
However, these promising results were counterbalanced by the loss of activity observed on 
the reactor vessel. Indeed, working without any base and cryptand induced typical adsorption 
of [18F]F- on the glass wall of the pyrex reactor (50.6 ± 8.4% of the starting activity, n = 22). To 
get around this problem, we tried several pretreatment strategies of the reactor surface (Figure 
5C). In most cases, the drying of small amounts of organic or mineral bases in the reactor 
before the radiofluorination reaction led to a significant decrease of the fixed activity on the 
glass. To prevent any side reaction and limit the number of competitive anions in the reaction 
mixture, we chose bases containing bulky cations and carbonate or hydrogen carbonate 
counterions (i.e. Cs2CO3, CsHCO3, Bu4NHCO3, etc). Unfortunately, all these attempts also led 
to a decrease of the fluorine-18 incorporation on the iodonium structure compared to the 
optimized conditions described above (no additive conditions, Figure 5C). 
 
Figure 5. Influence of: (i) the temperature, concentration (13 µmol of 6b in various volumes of solvent) and reaction time on the 
radiolabelling efficiency in diglyme (A) or toluene (B) and (ii) the addition of traces of mineral or organic bases in the reactor (C), % 
were calculated based on the starting [18F]F- activity; purity of the eluted compound was controlled by radio-TLC (>98%). 
3/ Deprotection step 
Finally, we turned our attention to the deprotection of the radiofluorinated intermediate [18F]9 
obtained after solid phase extraction. The loss of activity on the solid phase C18 cartridge was 
negligible (1.78 ± 0.02%, n = 67). Surprisingly, after concentration of the ethanolic eluate and 
final deprotection using a 3M aqueous H2SO4 solution at 140 °C for 5 min (reported by Kulk et 
al.[11]) radio-HPLC analysis of the reaction mixture revealed that only 16% of the total activity 
detected accounted for [18F]FDOPA. The other main radioactive component of the mixture was 
the corresponding methyl ester. An extended heating time of at least 15 min was necessary to 
achieve a full deprotection of the structure. To circumvent this problem and shorten the reaction 
time dedicated to the deprotection, concentrated HBr was used. After concentration of the 
eluate, heating at 140 °C for 10 min in 300 µL of concentrated HBr was then sufficient to 
achieve the complete deprotection of the structure and afford [18F]FDOPA without concomitant 
formation of radioactive by-products. After dilution of the reaction mixture with a 1 M aqueous 
solution of NH4OAc, the crude [18F]FDOPA was then easily purified by semi-preparative RP-
HPLC and collected to afford [18F]FDOPA in 15.2% RCY, >98% RCP, Am >150 GBq/µmol 
(n=3) and e.e. > 99% (chiral HPLC, n=3, see chromatograms in supplementary information).  
To further shorten the overall radiosynthesis time and minimize the harsh conditions required 
for the deprotection step, we investigated the acid-sensitive tert-butyl ester precursor 18b. The 
latter was obtained in five steps from the L-DOPA tert-butyl ester 12 according to the synthetic 
route described for 6b (Scheme 2). Precursor 12 was easily produced from commercially 
available L-tyrosine using tert-butyl acetate/perchloric acid esterification followed by NH-Boc 
protection and final oxidation of the aromatic ring into catechol using freshly prepared 2-
iodobenzoic acid.  
 
Scheme 2. Preparation of diaryliodonium salt 18b. Reagents and conditions: (a)  tert-butyl acetate, aq. HClO4 (70 wt%), 0 °C then 
RT, 12 h, 45%; (b) K2CO3, (Boc)2O, THF/H2O (1/1, v/v), RT, 3 h, 71%; (c) i) 2-iodoxybenzoic acid, DMF, RT, 30 min; ii) 1 M aq. 
ascorbic acid, 0 °C, 30 min, 97%; (d) C2H5OCH2Cl, DIPEA, THF, 0 °C then 40 °C, 24 h, 62%; (e) i) I2, K2CO3, PhI(OCOCF3)2, 
CH2Cl2, RT, 4 h, 58%; (f) i) NEt3, DMAP, (Boc)2O, MeCN, 40 °C, 24 h; ii) (Boc)2O, 40 °C, 23 h, 61%;  (g) Sn2Me6, Pd(PPh3)4, 1,4-
dioxane, reflux, 1.5 h, 76%; (h) i) p-MeOPh(IOAc)2, CH2Cl2, -40 °C, 1 h, ii) TFA, -40 °C, then RT, 5 h, 67%; (i) 1 M aq. NaOTf, 
CH2Cl2, RT, 85%. EOM: ethoxymethyl.    
We attempted the radiosynthesis of [18F]FDOPA using the precursor 18b and the optimal 
conditions described above for 6b. Direct elution of QMA-loaded [18F]F- was realised using a 
solution of 13 µmol of 18b in 750 µL anhydrous methanol (elution yield: 94.8 ± 3.2%, n = 8). 
The obtained eluate was evaporated under vacuum at 30 °C. Then, 200 µL of toluene were 
added to the reactor and heated at 110 °C for 10 min. Surprisingly, compared to the 
corresponding methyl ester, the protected radiofluorinated [18F]FDOPA was obtained, after 
solid phase C18 cartridge extraction, in higher radiolabelling efficiencies (29 ± 5%, n = 8). In 
order to validate the reproducibility of our radiosynthetic approach, the [18F]FDOPA was also 
produced from precursor 18b using a Raytest SynChrom R&D EVOIII bireactor automate in a 
partner laboratory. While some minor modifications of the protocol were mandatory to adapt 
the reaction conditions to this radiosynthesis module (see supplementary information), the 
protected intermediate of [18F]FDOPA was obtained in higher yields (i.e. 46 ± 4%, n = 3). After 
concentration of the eluate, deprotection using concentrated HCl at 120 °C for 7 min and 
purification via semipreparative RP-HPLC, final [18F]FDOPA was obtained in 64 min, 27-38% 
RCY d.c. (n = 5), >99% RCP, > 99% e.e., and high Am 170-230 GBq/µmol (Scheme 3). 
 
Scheme 3. A: In house preparation of [18F]FDOPA  from 6b following Kuik et al.[11] protocol compared to our radiosynthetic 
approach; B: Preparation of [18F]FDOPA from tert-butyl ester precursor 18b with our optimized protocol. Reagents and conditions: 
(a) [18F]KF-crypt-222-carbonate, diglyme, 140 °C, 5 min; (b) aq. H2SO4 3 M, 140 °C, 5 min; (c) [
18F]F-, toluene, 105-110 °C, 10 
min; (d) aq. HBr conc., 140 °C, 10 min; (e) aq. HCl conc., 120 °C, 7 min. EOM: ethoxymethyl.    
Conclusions 
We carried out a comprehensive optimization of the nucleophilic radiosynthetic approach to 
produce [18F]FDOPA with high molar activities from iodonium salt precursors. Our experiments 
clearly pointed out the importance of the HCO3- counterion for the efficiency of fluorine-18 
incorporation on such iodonium scaffolds. Considering that this new and fast nucleophilic 
radiosynthetic process for the automated production of [18F]FDOPA, free from any base, 
cryptand and metal catalyst, was evaluated on different automated systems implemented in 
two differents facilities (Clermont Ferrand and Strasbourg, France), we believe that it could be 
easily transferable to other laboratories and could provide an alternative to currently available 
[18F]FDOPA radiopharmaceutical production[7,22]. Finally, we assume that this methodology 
could be successfully applied to a broad range of iodonium salt precursors for radiofluorination 
of electron-rich aryl derivatives. 
Experimental Section 
Chemistry 
Experimental details, full data, 1H and 13C NMR spectra of compounds 6a-e, 7, 13-18a,b are 
available in Supporting Information. 
 
Radiochemistry 
 
1/ Radiosynthesis of [18F]FDOPA from precursor 6b using a bi-reactor SynChrom R&D 
EVOII syntheses module 
 
General experimental information 
No-carrier-added fluorine-18 (half-life: 109.8 min) was produced via the [18O(p, n)18F] nuclear 
reaction by irradiation of a 2.8 mL >97%-enriched [18O]H2O target (Bruce Technology) on a 
CPH14 cyclotron (14 MeV proton beam, Cyclopharma laboratories). Radio thin layer 
chromatography (radio-TLC) was performed on Merck pre-coated silica gel (60 F254) plates 
with a mixture ethyl acetate/cyclohexane (2/8, v/v) and measured on an AMBIS 400 
(Scanalytics, CSPI, San Diego, CA, USA). Analytical HPLC measurements were performed 
on a system consisting of an Agilent HP series 1100 (Hewlett Packard, Les Ulis, France) 
combined with a Flow one A500 Radiomatic detector (Packard, Canberra, Australia). A 
Reprosil Chiral-AA 8 µm column (250 x 4.6 mm; 8 µm; CIL Cluzeau; France) was used with 
water/acetonitrile (9/1, v/v) as isocratic eluent mixture and a flow of 0.7 mL/min. Unless 
otherwise indicated, all HPLC purifications and analyses were performed at λ=254 nm. 
Radiochemical syntheses and semi-preparative HPLC purifications were performed using a 
bi-reactor SynChrom R&D EVOII syntheses module (Raytest). Sep-Pak® Light Accell Plus 
QMA Cl- or carbonate cartridges (130 mg) and Sep-Pak® light C18 cartridges were purchased 
from Waters. Chromafix 30-PS-HCO3- QMA cartridges (46 mg) were purchased from ABX 
(Radeberg, Germany). A semi-preparative VP250/10 Nucleodur C18 HTec column (250 x 10 
mm; 8 µm; Macherey-Nagel) was used with water/ethanol (95/5, v/v) containing 0.1% 
trifluoroacetic acid as eluent at a flow of 2.5 mL/min. All radiolabelled compounds were 
compared by TLC and/or analytical HPLC to the authentic non-radioactive material and to be 
free of significant chemical and radiochemical impurities.  
 
Radiosynthesis 
The aqueous solution of [18F]F- in [18O]H2O obtained from Cyclopharma Laboratories was 
passed through an anion exchange resin (Sep-Pak® Light Accell Plus QMA Cl or carbonate 
cartridge, Waters, Trap 1, scheme S1, see supporting information). The cartridge was rinsed 
with 1 mL of anhydrous methanol (SC1, scheme S1) and dried for 2 min under vacuum and 
He flow (150 mL/min). Then, the radioactivity was eluted to the reactor using a solution of the 
precursor 6b (13 µmol) in anhydrous methanol (750 µL, SC2, scheme S1). The solvent was 
evaporated under reduced pressure at 30 °C under stirring. When the vacuum in the reactor 
was stabilized around 30-35 mbar, anhydrous toluene (200 µL) or diglyme (100 µL, SC3, 
scheme S1) were added to the reactor. The reaction mixture was then heated to 110 °C for 10 
min under stirring. The reactor was cooled to 50-60°C before addition of diglyme (500 µL, SC4, 
scheme S1) and water (19 mL, SC5, scheme S1) successively and under stirring. The solution 
was then passed through a Sep-Pak light C18 cartridge (Trap 2, scheme S1). After drying 
under He flow (250 mL/min), the cartridge was eluted to the second reactor using 2 mL of 
ethanol (SC6, scheme S1). The solvent was removed under vacuum at 70°C under stirring. 
Shortly before complete evaporation, concentrated bromhydric acid (300 µL, SC11, scheme 
S1) was added to the reaction mixture which was heated to 140°C for 10 min under stirring. 
After cooling to 35-40 °C, the dark brown/black reaction mixture was buffered using a 1 M 
aqueous solution of ammonium acetate (3 mL, SC7, scheme S1). The solution containing the 
crude unprotected [18F]FDOPA was purified via semi-preparative HPLC. The collected fraction 
(Rt = 10.5 min) was diluted in saline and analyzed by analytic radio-HPLC to determine the 
radiochemical purity, enantiomeric excess and specific activity. 
 
2/ Radiosynthesis of [18F]FDOPA from precursor 18b using a bi-reactor SynChrom R&D 
EVOIII syntheses module 
 
General experimental information 
No-carrier-added fluorine-18 (half-life: 109.8 min) was produced via the [18O(p, n)18F] nuclear 
reaction by irradiation of a 1 mL >97%-enriched [18O]H2O target (Huayi isotopes Co) on a TR24 
cyclotron (16-24 MeV proton beam, Advanced Cyclotron Systems Inc, ACSI). Radio thin layer 
chromatography (radio-TLC) was performed on Millipore aluminium back-coated silica gel (60 
F254) plates with a mixture of ethyl acetate/cyclohexane (2/8, v/v) and measured on a MiniGita 
apparatus (Raytest, Germany). Analytical HPLC measurements were performed on a system 
consisting of a Dionex U3000 HPLC (Thermo scientific, France) combined with a homemade 
radio-detector (connected to an UCI 50 interface, Thermo scientific, France) and a diode array 
detector. A Synchronis column (250 x 4.6 mm; 5 µm; Thermo scientific, France) was used with 
water/acetonitrile (9/1, v/v) as isocratic eluent mixture at a flow rate of 0.7 mL/min. Semi 
preparative HPLC purifications were performed at λ=254 nm. Radiochemical syntheses and 
semi-preparative HPLC purifications were performed using a bi-reactor SynChrom R&D EVOIII 
syntheses module (Raytest). Sep-Pak® Light Accell Plus QMA Cl- or carbonate cartridges (130 
mg) and Sep-Pak® light C18 cartridges were purchased from Waters. A semi-preparative 
VP250/10 Nucleodur C18 HTec column (250 x 10 mm; 5 µm; Macherey-Nagel) was used with 
water/ethanol (95/5, v/v) containing 0.1% trifluoroacetic acid as eluent at a flow rate of 2.5 
mL/min. 
The precursor 18b was stored in a desiccator over desiccant in the fridge (5 °C). After 2 months 
of storage decreasing yield were obtained (below 30% RCY decay corrected) and a new batch 
of precursor 18b was synthesised for further radiosyntheses. 
 
Radiosynthesis 
The aqueous solution of [18F]F- in [18O]H2O was transferred under helium pressure to an 
intermediate vial set in a well counter inside the hotcell (red dot square on scheme S2, see 
supporting information). After counting, the whole solution was transferred to the reception V-
vial of the Raytest module. [18F]F- in water was trapped on an anion exchange resin (Sep-Pak® 
Light Accell Plus QMA carbonate cartridge, Waters, Trap 1, scheme S2). The cartridge was 
rinsed with 1 mL of anhydrous methanol (SC1, scheme S2) and dried under vacuum and argon 
flow. The radioactivity was eluted into the reactor using a solution of the precursor 18b (13 
µmol) in anhydrous methanol (850 µL, SC2, scheme S2). The solvent was evaporated under 
reduced pressure at 28 °C under stirring. When the vacuum in the reactor was stabilized 
around 50 mbar, anhydrous toluene (250 µL, SC3, scheme S2) was added to the reactor. The 
reaction mixture was then heated to 105 °C for 5 min and 110 °C for 5 min more under stirring. 
The reactor was cooled to 50°C before addition of water (12-13 mL, SC4, scheme S2) under 
stirring. The solution was then passed through a Sep-Pak light C18 cartridge (Trap 2, scheme 
S2). After drying under argon flow, 2.2 mL of acetonitrile (SC5, scheme S2) were added into 
the reactor and then transferred onto the C18 cartridge. The cartridge was eluted to the second 
reactor and the solvent was removed under reduced pressure at 70°C under stirring. 
Acetonitrile (250 µL, SC6) and concentrated hydrochloric acid (750 µL in an intermediate V-
Vial isolated between valve C1 and D4 to avoid HCl contamination) was added. The reaction 
mixture was heated to 120°C for 7 min under stirring. After cooling to 40 °C, the dark black 
reaction mixture was buffered using a 1 M aqueous solution of ammonium acetate (4 mL, SC8, 
scheme S2). The solution containing the crude [18F]FDOPA was transferred to the HPLC loop 
(5 mL) and purified via semi-preparative HPLC (95/5, v/v, Water/Ethanol containing 0,1% 
TFA). The collected fraction (Rt = 8.5 min) was analyzed by analytic radio-HPLC to determine 
the radiochemical purity, enantiomeric excess and specific activity. 
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